Search

Your search keyword '"De Reijke, Theo"' showing total 994 results
Start Over Author "De Reijke, Theo"
994 results on '"De Reijke, Theo"'

1. Transperineal Laser Ablation Treatment for Lower Urinary Tract Symptoms Due to Benign Prostatic Obstruction: Protocol for a Prospective In Vivo Pilot Study

Author

van Kollenburg, Rob A A, van Riel, Luigi A M J G, Bloemen, Paul R, Oddens, Jorg R, de Reijke, Theo M, Beerlage, Harrie P, and de Bruin, Daniel Martijn

Subjects
Medicine, Computer applications to medicine. Medical informatics, R858-859.7
Abstract

BackgroundStandard surgical treatments for lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) use a transurethral approach. Drawbacks are the need for general or spinal anesthesia and complications such as hematuria, strictures, and cloth retention. Therefore, a minimal invasive technique under local anesthesia is desired to improve patient safety. Recently, SoracteLite transperineal laser ablation (TPLA) has been introduced as a novel minimal invasive treatment for BPO. The system used is unique because 4 laser sources are independently available. This 1064-nm diode laser induces coagulative necrosis. Moreover, TPLA is unique because it has a transperineal approach and can be performed under local anesthesia in an outpatient setting. ObjectiveThe primary objective of this study is to determine the safety and feasibility of TPLA treatment for men, who are fit for standard surgery, with LUTS due to BPO. The secondary objectives are to determine functional outcomes by flowmetry and patient-reported outcome measures (PROMs), side effects, and tissue changes observed on imaging. MethodsThis study is a prospective, single center, interventional pilot study IDEAL framework stage 2a and will include 20 patients. Eligible patients are men ≥40 years of age, with a prostate volume of 30 to 120 cc, have urodynamically proven bladder outlet obstruction, and have a peak urinary flow of 5 to 15 mL per second. All patients will undergo TPLA of their prostate under local anesthesia by using the EchoLaser system. Depending on the prostate volume, 2 to 4 laser fibers will be placed bilaterally into the prostate. Patient follow-up consists of uroflowmetry, PROMs, and imaging by using contrast-enhanced ultrasound. Total follow-up is 12 months following treatment. ResultsPresently, recruitment of patients is ongoing. Publication of first results is expected by early 2020. ConclusionsTPLA offers the potential to be a novel minimal invasive technique for treatment of LUTS due to BPO in men fit for standard desobstruction. This study will evaluate the safety and feasibility of TPLA and report on functional outcomes and tissue changes observed on imaging following TPLA treatment. International Registered Report Identifier (IRRID)DERR1-10.2196/15687

Published
2020
Full Text
View/download PDF

3. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

Author

Roy, Soumyajit, Romero, Tahmineh, Michalski, Jeff, Feng, Felix, Efstathiou, Jason, Lawton, Colleen, Bolla, Michel, Maingon, Philippe, de Reijke, Theo, Joseph, David, Ong, Wee, Sydes, Matthew, Dearnaley, David, Tree, Alison, Carrier, Nathalie, Nabid, Abdenour, Souhami, Luis, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen, Maldonado, Xavier, Reiter, Robert, Nickols, Nicholas, Ma, T, Farrell, Matthew, Neilsen, Beth, Juarez, Jesus, Deng, Jie, Vangala, Sitaram, Avril, Norbert, Jia, Angela, Zaorsky, Nicholas, Sun, Yilun, Spratt, Daniel, Kishan, Amar, Rettig, Matthew, Steinberg, Michael, and Valle, Luca

Subjects
Male, Humans, Prostate, Prostatic Neoplasms, Androgen Antagonists, Prostate-Specific Antigen, Adenocarcinoma
Abstract

PURPOSE: The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the surrogacy of BCR using different surrogacy analytic methods. MATERIALS AND METHODS: Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed using the Prentice criteria (including landmark analyses) and the two-stage meta-analytic approach (estimating Kendalls tau and the R2). Biochemical recurrence-free survival (BCRFS, time from random assignment to BCR or any death) and time to BCR (TTBCR, time from random assignment to BCR or cancer-specific deaths censoring for noncancer-related deaths) were assessed. RESULTS: Overall, 10,741 patients were included. Dose escalation, addition of short-term ADT, and prolongation of ADT duration significantly improved BCR (hazard ratio [HR], 0.71 [95% CI, 0.63 to 0.79]; HR, 0.53 [95% CI, 0.48 to 0.59]; and HR, 0.54 [95% CI, 0.48 to 0.61], respectively). Adding short-term ADT (HR, 0.91 [95% CI, 0.84 to 0.99]) and prolonging ADT (HR, 0.86 [95% CI, 0.78 to 0.94]) significantly improved OS, whereas dose escalation did not (HR, 0.98 [95% CI, 0.87 to 1.11]). BCR at 48 months was associated with inferior OS in all three groups (HR, 2.46 [95% CI, 2.08 to 2.92]; HR, 1.51 [95% CI, 1.35 to 1.70]; and HR, 2.31 [95% CI, 2.04 to 2.61], respectively). However, after adjusting for BCR at 48 months, there was no significant treatment effect on OS (HR, 1.10 [95% CI, 0.96 to 1.27]; HR, 0.96 [95% CI, 0.87 to 1.06] and 1.00 [95% CI, 0.90 to 1.12], respectively). The patient-level correlation (Kendalls tau) for BCRFS and OS ranged between 0.59 and 0.69, and that for TTBCR and OS ranged between 0.23 and 0.41. The R2 values for trial-level correlation of the treatment effect on BCRFS and TTBCR with that on OS were 0.563 and 0.160, respectively. CONCLUSION: BCRFS and TTBCR are prognostic but failed to satisfy all surrogacy criteria. Strength of correlation was greater when noncancer-related deaths were considered events.

Published
2023

6. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials

Author

Martin, Ting, Sun, Yilun, Malone, Shawn, Roach, Mack, Dearnaley, David, Pisansky, Thomas M, Feng, Felix Y, Sandler, Howard M, Efstathiou, Jason A, Syndikus, Isabel, Hall, Emma C, Tree, Alison C, Sydes, Matthew R, Cruickshank, Claire, Roy, Soumyajit, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Zapatero, Almudena, Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Romero, Tahmineh, Steinberg, Michael L, Valle, Luca F, Rettig, Matthew B, Nickols, Nicholas G, Shoag, Jonathan E, Reiter, Robert E, Zaorsky, Nicholas G, Jia, Angela Y, Garcia, Jorge A, Spratt, Daniel E, Kishan, Amar U, and Investigators, on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate Consortium

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Clinical Research, Patient Safety, Urologic Diseases, Cancer, Prostate Cancer, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Good Health and Well Being, Male, Humans, Prostatic Neoplasms, Androgen Antagonists, Androgens, Randomized Controlled Trials as Topic, Prostate-Specific Antigen, Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeThe sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).Materials and methodsIndividual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality.ResultsOverall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT.ConclusionADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT.

Published
2023

7. Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: The results of a Delphi consensus project

Author

Cocci, Andrea, Pezzoli, Marta, Bianco, Fernando, Blefari, Franco, Bove, Pierluigi, Cornud, Francois, De Rienzo, Gaetano, Destefanis, Paolo, Di Trapani, Danilo, Giacobbe, Alessandro, Giovanessi, Luca, Laganà, Antonino, Lughezzani, Giovanni, Manenti, Guglielmo, Muto, Gianluca, Patelli, Gianluigi, Pinzi, Novello, Regusci, Stefano, Russo, Giorgio I., Salamanca, Juan I.M., Salvi, Matteo, Silvestri, Luigi, Verweij, Fabrizio, Walser, Eric, Bertolo, Riccardo G., Iacovelli, Valerio, Bertaccini, Alessandro, Marchiori, Debora, Davila, Hugo, Ditonno, Pasquale, Gontero, Paolo, Iapicca, Gennaro, M De Reijke, Theo, Ricapito, Vito, Pellegrini, Pierluca, Minervini, Andrea, Serni, Sergio, and Sessa, Francesco

Published
2024
Full Text
View/download PDF

8. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement

Author

Deivasigamani, Sriram, Kotamarti, Srinath, Rastinehad, Ardeshir R., Salas, Rafael Sanchez, de la Rosette, J.J.M.C.H., Lepor, Herbert, Pinto, Peter, Ahmed, Hashim U., Gill, Inderbir, Klotz, Laurence, Taneja, Samir S., Emberton, Mark, Lawrentschuk, Nathan, Wysock, James, Feller, John F., Crouzet, Sebastien, Kumar M., Praveen, Seguier, Denis, Adams, Eric S., Michael, Zoe, Abreu, Andre, Jack Tay, Kae, Ward, John F., Shinohara, Katsuto, Katz, Aaron E., Villers, Arnauld, Chin, Joseph L., Stricker, Phillip D., Baco, Eduard, Macek, Petr, Ahmad, Ardalan E., Chiu, Peter K.F., Crawford, E. David, Rogers, Craig G., Futterer, Jurgen J., Rais-Bahrami, Soroush, Robertson, Cary N., Hadaschik, Boris, Marra, Giancarlo, Valerio, Massimo, Chong, Kian Tai, Kasivisvanathan, Veeru, Tan, Wei Phin, Lomas, Derek, Walz, Jochen, Guimaraes, Gustavo Cardoso, Mertziotis, Nikos I., Becher, Ezequiel, Finelli, Antonio, Kasraeian, Ali, Lebastchi, Amir H., Vora, Anup, Rosen, Mark A., Bakir, Baris, Arcot, Rohit, Yee, Samuel, Netsch, Christopher, Meng, Xiaosong, de Reijke, Theo M., Tan, Yu Guang, Regusci, Stefano, Benjamin, Tavya G.R., Olivares, Ruben, Noureldin, Mohamed, Bianco, Fernando J., Sivaraman, Arjun, Kim, Fernando J., Given, Robert W., Dason, Shawn, Sheetz, Tyler J., Shoji, Sunao, Schulman, Ariel, Royce, Peter, Shah, Taimur T., Scionti, Stephen, Salomon, Georg, Laguna, Pilar, Tourinho-Barbosa, Rafael, Aminsharifi, Alireza, Cathelineau, Xavier, Gontero, Paolo, Stabile, Armando, Grummet, Jeremy, Ledbetter, Leila, Graton, Margaret, Stephen Jones, J., and Polascik, Thomas J.

Published
2023
Full Text
View/download PDF

9. Reliable Visualization of the Treatment Effect of Transperineal Focal Laser Ablation in Prostate Cancer Patients by Magnetic Resonance Imaging and Contrast-enhanced Ultrasound Imaging

Author

van Riel, Luigi A.M.J.G., van Kollenburg, Rob A.A., Freund, Jan Erik, Almasian, Mitra, Jager, Auke, Engelbrecht, Marc R.W., Smit, Ruth S., Bekers, Elise, Nieuwenhuijzen, Jakko A., van Leeuwen, Pim J., van der Poel, Henk, de Reijke, Theo M., Beerlage, Harrie P., Oddens, Jorg R., and de Bruin, Daniel M.

Published
2023
Full Text
View/download PDF

11. Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials

Author

Kishan, Amar U, Chu, Fang-I, King, Christopher R, Seiferheld, Wendy, Spratt, Daniel E, Tran, Phuoc, Wang, Xiaoyan, Pugh, Stephanie E, Sandler, Kiri A, Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Nickols, Nicholas G, Rettig, Matthew, Drakaki, Alexandra, Liu, Sandy T, Reiter, Robert E, Chang, Albert J, Feng, Felix Y, Sajed, Dipti, Nguyen, Paul L, Kupelian, Patrick A, Steinberg, Michael L, Boutros, Paul C, Elashoff, David, Collette, Laurence, and Sandler, Howard M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Prostate Cancer, Radiation Oncology, Cancer, Aging, Clinical Trials and Supportive Activities, Urologic Diseases, Clinical Research, Humans, Male, Neoplasm Grading, Prostatic Neoplasms, Randomized Controlled Trials as Topic, Treatment Failure, Local failure, Radiotherapy, High grade, Urology & Nephrology, Clinical sciences
Abstract

BackgroundThe importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.ObjectiveTo evaluate the clinical implications of LF after definitive RT.Design, setting, and participantsIndividual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials.Outcome measurements and statistical analysisMultivariable Cox proportional hazard models were developed to evaluate the relationship between overall survival (OS), PCa-specific survival (PCSS), and distant metastasis (DM)-free survival (DMFS) and LF as a time-dependent covariate. Markov proportional hazard models were developed to evaluate the impact of specific transitions between disease states on these endpoints.Results and limitationsMedian follow-up was 6.4 yr overall and 7.2 yr for surviving patients. LF was significantly associated with OS (hazard ratio [HR] 1.70 [95% confidence interval {CI} 1.37-2.10]), PCSS (3.10 [95% CI 2.33-4.12]), and DMFS (HR 1.92 [95% CI 1.54-2.39]), p

Published
2020

13. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation—A Multicenter Validation Study

Author

Geboers, Bart, Gondoputro, William, Thompson, James E., Reesink, Daan J., van Riel, Luigi A.M.J.G., Zhang, David, Blazevski, Alexandar, Doan, Paul, Agrawal, Shikha, Matthews, Jayne, Haynes, Anne-Maree, Liu, Zhixin, Delprado, Warrick, Shnier, Ron, de Reijke, Theo M., Lawrentschuk, Nathan, Stijns, Pascal E.F., Yaxley, John W., Scheltema, Matthijs J., and Stricker, Phillip D.

Published
2022
Full Text
View/download PDF

14. Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)

Author

Ma, Ting Martin, Chu, Fang-I, Sandler, Howard, Feng, Felix Y., Efstathiou, Jason A., Jones, Christopher U., Roach, Mack, 3rd, Rosenthal, Seth A., Pisansky, Thomas, Michalski, Jeff M., Bolla, Michel, de Reijke, Theo M., Maingon, Philippe, Neven, Anouk, Denham, James, Steigler, Allison, Joseph, David, Nabid, Abdenour, Souhami, Luis, Carrier, Nathalie, Incrocci, Luca, Heemsbergen, Wilma, Pos, Floris J., Sydes, Matthew R., Dearnaley, David P., Tree, Alison C., Syndikus, Isabel, Hall, Emma, Cruickshank, Clare, Malone, Shawn, Roy, Soumyajit, Sun, Yilun, Zaorsky, Nicholas G., Nickols, Nicholas G., Reiter, Robert E., Rettig, Matthew B., Steinberg, Michael L., Reddy, Vishruth K., Xiang, Michael, Romero, Tahmineh, Spratt, Daniel E., and Kishan, Amar U.

Published
2022
Full Text
View/download PDF

16. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient–data Network Meta-analysis from the MARCAP Consortium

Author

Kishan, Amar U., Wang, Xiaoyan, Sun, Yilun, Romero, Tahmineh, Michalski, Jeff M., Ma, Ting Martin, Feng, Felix Y., Sandler, Howard M., Bolla, Michel, Maingon, Philippe, De Reijke, Theo, Neven, Anouk, Steigler, Allison, Denham, James W., Joseph, David, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Sydes, Matt R., Dearnaley, David P., Syndikus, Isabel, Tree, Alison C., Incrocci, Luca, Heemsbergen, Wilma D., Pos, Floris J., Zapatero, Almudena, Efstathiou, Jason A., Guerrero, Araceli, Alvarez, Ana, San-Segundo, Carmen Gonzalez, Maldonado, Xavier, Xiang, Michael, Rettig, Matthew B., Reiter, Robert E., Zaorsky, Nicholas G., Ong, Wee Loon, Dess, Robert T., Steinberg, Michael L., Nickols, Nicholas G., Roy, Soumyajit, Garcia, Jorge A., and Spratt, Daniel E.

Published
2022
Full Text
View/download PDF

19. Advanced optical imaging techniques for bladder cancer detection and diagnosis: a systematic review.

Author

Remmelink, Marinka J., Rip, Yael, Nieuwenhuijzen, Jakko A., Ket, Johannes C.F., Oddens, Jorg R., de Reijke, Theo M., and de Bruin, Daniel M.

Subjects
CANCER diagnosis, MICROSCOPY, OPTICAL coherence tomography, ACOUSTIC imaging, OPTICAL images
Abstract

Objectives: To systematically assess the current available literature concerning advanced optical imaging methods for the detection and diagnosis of bladder cancer (BCa), focusing particularly on the sensitivity and specificity of these techniques. Methods: First a scoping search was performed to identify all available optical techniques for BCa detection and diagnosis. The optical imaging techniques used for detecting BCa are: the Storz professional image enhancement system (IMAGE1 S), narrow‐band imaging (NBI), photoacoustic imaging (PAI), autofluorescence imaging (AFI), photodynamic diagnosis (PDD), and scanning fibre endoscopy (SFE). The staging and grading techniques for BCa are: optical coherence tomography (OCT), confocal laser endomicroscopy (CLE), Raman spectroscopy, endocytoscopy, and non‐linear optical microscopy (NLO). Then a systematic literature search was conducted using MEDLINE, EMBASE and Web of Science from inception to 21 November 2023. Articles were screened and selected by two independent reviewers. Inclusion criteria were: reporting on both the sensitivity and specificity of a particular technique and comparison to histopathology, and in the case of a detection technique comparison to white light cystoscopy (WLC). Results: Out of 6707 articles, 189 underwent full‐text review, resulting in 52 inclusions. No articles met criteria for IMAGE1 S, PAI, SFE, Raman spectroscopy, and endocytoscopy. All detection techniques showed higher sensitivity than WLC, with NBI leading (87.8–100%). Overall, detection technique specificity was comparable to WLC, with PDD being most specific (23.3–100%). CLE and OCT varied in sensitivity and specificity, with OCT showing higher specificity for BCa diagnosis, notably for carcinoma in situ (97–99%) compared to CLE (62.5–81.3%). NLO demonstrated high sensitivity and specificity (90–97% and 77–100%, respectively) based on limited data from two small ex vivo studies. Conclusions: Optical techniques with the most potential are PDD for detecting and OCT for staging and grading BCa. Further research is crucial to validate their integration into routine practice and explore the value of other imaging techniques. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis

Author

Kishan, Amar U, Sun, Yilun, Hartman, Holly, Pisansky, Thomas M, Bolla, Michel, Neven, Anouk, Steigler, Allison, Denham, James W, Feng, Felix Y, Zapatero, Almudena, Armstrong, John G, Nabid, Abdenour, Carrier, Nathalie, Souhami, Luis, Dunne, Mary T, Efstathiou, Jason A, Sandler, Howard M, Guerrero, Araceli, Joseph, David, Maingon, Philippe, de Reijke, Theo M, Maldonado, Xavier, Ma, Ting Martin, Romero, Tahmineh, Wang, Xiaoyan, Rettig, Matthew B, Reiter, Robert E, Zaorsky, Nicholas G, Steinberg, Michael L, Nickols, Nicholas G, Jia, Angela Y, Garcia, Jorge A, and Spratt, Daniel E

Published
2022
Full Text
View/download PDF

25. Grading urothelial carcinoma with probe-based confocal laser endomicroscopy during flexible cystoscopy

Author

Pathologie Pathologen staf, Cancer, de Ruiter, Ben Max, Freund, Jan Erik, Savci-Heijnink, C. Dilara, van Hattum, Jons W., de Reijke, Theo M., Baard, Joyce, Kamphuis, Guido M., de Bruin, D. Martijn, Oddens, Jorg R., Pathologie Pathologen staf, Cancer, de Ruiter, Ben Max, Freund, Jan Erik, Savci-Heijnink, C. Dilara, van Hattum, Jons W., de Reijke, Theo M., Baard, Joyce, Kamphuis, Guido M., de Bruin, D. Martijn, and Oddens, Jorg R.

Published
2024

26. Grading urothelial carcinoma with probe-based confocal laser endomicroscopy during flexible cystoscopy.

Author

de Ruiter, Ben-Max, Freund, Jan Erik, Savci-Heijnink, C. Dilara, van Hattum, Jons W., de Reijke, Theo M., Baard, Joyce, Kamphuis, Guido M., de Bruin, D. Martijn, and Oddens, Jorg R.

Subjects
BLADDER cancer, CYSTOSCOPY, TRANSURETHRAL resection of bladder, TRANSITIONAL cell carcinoma, BENIGN tumors, LASERS
Abstract

Purpose: Urothelial bladder cancer (UCB) care requires frequent follow-up cystoscopy and surgery. Confocal laser endomicroscopy (CLE) is a probe-based optical technique that can provide real-time microscopic evaluation with the potential for outpatient grading of UCB. This study aims to investigate the diagnostic accuracy and interobserver variability for the grading of UCB with CLE during flexible cystoscopy (fCLE). Methods: Participants scheduled for transurethral resection of papillary bladder tumors were prospectively included for intra-operative fCLE. Exclusion criteria were flat lesions, fluorescein allergy or pregnancy. Two independent observers evaluated fCLE, classifying tumors as low- or high-grade urothelial carcinoma (LGUC/HGUC) or benign. Interobserver agreement was calculated with Cohens kappa (κ) and diagnostic accuracy with 2 × 2 tables. Histopathology was the reference test. Results: Histopathology of 34 lesions revealed 14 HGUC, 14 LGUC and 6 benign tumors. Diagnostic yield for fCLE was 80–85% with a κ of 0.75. Respectively, sensitivity, specificity, NPV and PPV were: for benign tumors 0–20%, 96–100%, unmeasureable-50% and 87%, for LGUC 57–64%, 41–58%, 44–53% and 54–69% and for HGUC 38–57%, 56–68%, 38–57% and 56–68%, with an interobserver agreement of κ 0.61. Conclusion: fCLE is currently insufficient to grade UCB. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Therapeutic prostate cancer interventions: a systematic review on pubic arch interference and needle positioning errors.

Author

Bloemberg, Jette, de Vries, Martijn, van Riel, Luigi A. M. J. G., de Reijke, Theo M., Sakes, Aimée, Breedveld, Paul, and van den Dobbelsteen, John J.

Subjects
PROSTATE, PROSTATE cancer, RADIOISOTOPE brachytherapy, CANCER treatment, PHYSICIANS
Abstract

Introduction: This study focuses on the quantification of and current guidelines on the hazards related to needle positioning in prostate cancer treatment: (1) access restrictions to the prostate gland by the pubic arch, so-called Pubic Arch Interference (PAI) and (2) needle positioning errors. Next, we propose solution strategies to mitigate these hazards. Methods: The literature search was executed in the Embase, Medline ALL, Web of Science Core Collection*, and Cochrane Central Register of Controlled Trials databases. Results: The literature search resulted in 50 included articles. PAI was reported in patients with various prostate volumes. The level of reported PAI varied between 0 and 22.3 mm, depending on the patient's position and the measuring method. Low-Dose-Rate Brachytherapy induced the largest reported misplacement errors, especially in the cranio-caudal direction (up to 10 mm) and the largest displacement errors were reported for High-Dose-Rate Brachytherapy in the cranio-caudal direction (up to 47 mm), generally increasing over time. Conclusions: Current clinical guidelines related to prostate volume, needle positioning accuracy, and maximum allowable PAI are ambiguous, and compliance in the clinical setting differs between institutions. Solutions, such as steerable needles, assist in mitigating the hazards and potentially allow the physician to proceed with the procedure. This systematic review was performed in accordance with the PRISMA guidelines. The review was registered at Protocols.io (DOI: dx.doi.org/10.17504/protocols.io.6qpvr89eplmk/v1). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting

Author

Aluwini, Shafak S., Mehra, Niven, Lolkema, Martijn P., Oprea-Lager, Daniela E., Yakar, Derya, Stoevelaar, Herman, van der Poel, Henk, Busstra, Martijn, de Jong, Igle-Jan, de Reijke, Theo, de Vries, Kim, Heijmink, Stijn, Jenster, Guido, Klaver, Sjoerd, Kneppers, Jeroen, Lavalaye, Jules, Leyten, Gisèle, Moonen, Luc, Nagaraj, James, Noordzij, Walter, Osanto, Susanne, Oving, Irma, Schaake, Eva, Scheenen, Tom, Schoots, Ivo, Sedelaar, Michiel, Somford, Diederik, van den Berkmortel, Franchette, van der Hulle, Tom, van der Voort van Zyp, Jochem, van Leeuwen, Pim, van Moorselaar, Jeroen, van Oort, Inge, Vogel, Wouter, and Westgeest, Hans

Published
2020
Full Text
View/download PDF

30. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer

Author

Brausi, Maurizio, Hoskin, Peter, Andritsch, Elisabeth, Banks, Ian, Beishon, Marc, Boyle, Helen, Colecchia, Maurizio, Delgado-Bolton, Roberto, Höckel, Michael, Leonard, Kay, Lövey, József, Maroto, Pablo, Mastris, Ken, Medeiros, Rui, Naredi, Peter, Oyen, Raymond, de Reijke, Theo, Selby, Peter, Saarto, Tiina, Valdagni, Riccardo, Costa, Alberto, and Poortmans, Philip

Published
2020
Full Text
View/download PDF

31. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees

Author

Witjes, J. Alfred, Babjuk, Marek, Bellmunt, Joaquim, Bruins, H. Maxim, De Reijke, Theo M., De Santis, Maria, Gillessen, Silke, James, Nicholas, Maclennan, Steven, Palou, Juan, Powles, Tom, Ribal, Maria J., Shariat, Shahrokh F., Der Kwast, Theo Van, Xylinas, Evanguelos, Agarwal, Neeraj, Arends, Tom, Bamias, Aristotle, Birtle, Alison, Black, Peter C., Bochner, Bernard H., Bolla, Michel, Boormans, Joost L., Bossi, Alberto, Briganti, Alberto, Brummelhuis, Iris, Burger, Max, Castellano, Daniel, Cathomas, Richard, Chiti, Arturo, Choudhury, Ananya, Compérat, Eva, Crabb, Simon, Culine, Stephane, De Bari, Berardino, De Blok, Willem, J.L. De Visschere, Pieter, Decaestecker, Karel, Dimitropoulos, Konstantinos, Dominguez-Escrig, Jose L., Fanti, Stefano, Fonteyne, Valerie, Frydenberg, Mark, Futterer, Jurgen J., Gakis, Georgios, Geavlete, Bogdan, Gontero, Paolo, Grubmüller, Bernhard, Hafeez, Shaista, Hansel, Donna E., Hartmann, Arndt, Hayne, Dickon, Henry, Ann M., Hernandez, Virginia, Herr, Harry, Herrmann, Ken, Hoskin, Peter, Huguet, Jorge, Jereczek-Fossa, Barbara A., Jones, Rob, Kamat, Ashish M., Khoo, Vincent, Kiltie, Anne E., Krege, Susanne, Ladoire, Sylvain, Lara, Pedro C., Leliveld, Annemarie, Linares-Espinós, Estefania, Løgager, Vibeke, Lorch, Anja, Loriot, Yohann, Meijer, Richard, Mir, M. Carmen, Moschini, Marco, Mostafid, Hugh, Müller, Arndt-Christian, Müller, Christoph R., N'Dow, James, Necchi, Andrea, Neuzillet, Yann, Oddens, Jorg R., Oldenburg, Jan, Osanto, Susanne, J.G. Oyen, Wim, Pacheco-Figueiredo, Luís, Pappot, Helle, Patel, Manish I., Pieters, Bradley R., Plass, Karin, Remzi, Mesut, Retz, Margitta, Richenberg, Jonathan, Rink, Michael, Roghmann, Florian, Rosenberg, Jonathan E., Rouprêt, Morgan, Rouvière, Olivier, Salembier, Carl, Salminen, Antti, Sargos, Paul, Sengupta, Shomik, Sherif, Amir, Smeenk, Robert J., Smits, Anita, Stenzl, Arnulf, Thalmann, George N., Tombal, Bertrand, Turkbey, Baris, Lauridsen, Susanne Vahr, Valdagni, Riccardo, Van Der Heijden, Antoine G., Van Poppel, Hein, Vartolomei, Mihai D., Veskimäe, Erik, Vilaseca, Antoni, Rivera, Franklin A. Vives, Wiegel, Thomas, Wiklund, Peter, Williams, Andrew, Zigeuner, Richard, and Horwich, Alan

Published
2020
Full Text
View/download PDF

39. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer.

Author

Rodríguez-Sánchez, Lara, Emberton, Mark, de Reijke, Theo, Stricker, Phillip, Miñana, Bernardino, Bianco, Fernando, Dominguez Escrig, Jose Luis, Lantz, Anna, and Sanchez-Salas, Rafael

Subjects
THERAPEUTICS, DELPHI method, PROSTATE cancer
Abstract

This document is a list of references and sources related to the topic of focal therapy for prostate cancer. It includes studies, clinical trials, and research papers that explore various treatment options and techniques, such as high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE), and photodynamic therapy. The document also mentions the importance of accurate imaging techniques, such as magnetic resonance imaging (MRI) and prostate-specific membrane antigen (PSMA) PET-CT, in guiding and assessing the effectiveness of focal therapy. The references provide a comprehensive overview of the current research and ongoing studies in the field of focal therapy for prostate cancer. [Extracted from the article]

Published
2024
Full Text
View/download PDF

40. Perturbation of Copper Homeostasis Sensitizes Cancer Cells to Elevated Temperature

Author

Scutigliani, Enzo M., primary, van Hattum, Jons, additional, Lobo-Cerna, Fernando, additional, Kruyswijk, Joanne, additional, Myrcha, Maja, additional, Dekkers, Frederique E. G. A., additional, Hoebe, Ron A., additional, Edwards, Finn, additional, Oppelaar, Jetta J., additional, Vogt, Liffert, additional, Bootsma, Sanne, additional, Bijlsma, Maarten F., additional, Picavet, Daisy I., additional, Crezee, Johannes, additional, Oddens, Jorg R., additional, de Reijke, Theo M., additional, and Krawczyk, Przemek M., additional

Published
2023
Full Text
View/download PDF

42. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy

Author

Mannaerts, Christophe K., Gayet, Maudy, Verbeek, Jan F., Engelbrecht, Marc R.W., Savci-Heijink, C. Dilara, Jager, Gerrit J., Gielens, Maaike P.M., van der Linden, Hans, Beerlage, Harrie P., de Reijke, Theo M., Wijkstra, Hessel, and Roobol, Monique J.

Published
2018
Full Text
View/download PDF

46. A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer

Author

de la Rosette, Jean, Dominguez-Escrig, Jose, Zhang, Kai, Teoh, Jeremy, Barret, Eric, Ramon-Borja, Juan Casanova, Muir, Gordon, Bohr, Julia, de Reijke, Theo, Ng, Chi-Fai, Leung, Chi-Ho, Sanchez-Salas, Rafael, Laguna, Pilar, Urology, APH - Personalized Medicine, APH - Quality of Care, and CCA - Imaging and biomarkers

Subjects
electroporation, quality of life, Urology, drug-related side effects and adverse reactions, prostatic neoplasms
Abstract

PURPOSE: Our goal was to evaluate the effect of focal vs extended irreversible electroporation on side effects, patient-reported quality of life, and early oncologic control for localized low-intermediate risk prostate cancer patients. MATERIALS AND METHODS: Men with localized low-intermediate risk prostate cancer were randomized to receive focal or extended irreversible electroporation ablation. Quality of life was measured by International Index of Erectile Function, Expanded Prostate Cancer Index Composite questionnaire, and International Prostate Symptom Score. RESULTS: A total of 51 and 55 patients underwent focal and extended irreversible electroporation, respectively. The median follow-up time was 30 months. Rates of erectile dysfunction and rates of adverse events were similar between the 2 groups at 3 months. The focal ablation group seemed to have better International Index of Erectile Function scores at 3 months; it also had a better Expanded Prostate Cancer Index Composite-sexual function score than the extended ablation group across time that was close to statistical significance (mean difference 1.4; 95% CI -0.13 to 2.9, P = .073). There were no significant differences between the 2 groups in other quality-of-life measures. Upon prostate biopsy at 6 months, the rate of residual clinically significant prostate cancer (Gleason ≥3 + 4) was 18.8% and 13.2% in the focal and extended irreversible electroporation groups, respectively, without significant differences. CONCLUSIONS: Focal and extended irreversible electroporation ablation had similar safety profile, urinary function, and oncologic outcomes in men with localized low-intermediate risk prostate cancer. In addition, focal ablation demonstrated superior erectile function outcome over extended irreversible electroporation in the first 3-6 months.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results